Hyloris Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Hyloris Pharmaceuticals has a total shareholder equity of €48.1M and total debt of €8.6M, which brings its debt-to-equity ratio to 17.9%. Its total assets and total liabilities are €63.4M and €15.4M respectively.
Key information
17.9%
Debt to equity ratio
€8.62m
Debt
| Interest coverage ratio | n/a |
| Cash | €50.54m |
| Equity | €48.06m |
| Total liabilities | €15.39m |
| Total assets | €63.44m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 52U's short term assets (€54.0M) exceed its short term liabilities (€15.0M).
Long Term Liabilities: 52U's short term assets (€54.0M) exceed its long term liabilities (€410.0K).
Debt to Equity History and Analysis
Debt Level: 52U has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 52U's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 52U has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 52U has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 27.1% each year.